56 Days
Source:
مأرب برس
Source: مأرب برس
56 Daysمأرب برس
Source: مأرب برس
56 DaysReady to play
Ready to play
Reports indicate that the Danish pharmaceutical company "GlaxoSmithKline" plans to introduce a new seasonal flu vaccine to European markets by early 2026, following highly successful clinical trial results. It is believed that the new vaccine offers broader protection against various influenza strains and provides longer-lasting immunity, reducing the need for annual vaccinations. Registration of the vaccine in the European Union is expected to commence in early 2025, as part of efforts to improve the world's response to seasonal pandemics.
Notice: This Is an AI-Generated Summary
Comments (0)